SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (4132)6/15/2001 5:17:23 PM
From: Biomaven  Read Replies (3) | Respond to of 52153
 
And for some "homework" over the weekend, I would strongly encourage people to listen to the HGSI analyst day presentation. I was extremely impressed, and I learnt a lot.

Incidentally, they have re-iterated their 100k (or more) human gene claim on an "apples to apples" basis (not counting alternative splicings as multiple genes). Haseltine noted with some amusement that the Genome Project count had already increased (now standing at about 37k). I don't really think it matters that much from an investment viewpoint, but it's still a fun controversy.

Peter



To: Biomaven who wrote (4132)6/15/2001 7:15:44 PM
From: nigel bates  Read Replies (1) | Respond to of 52153
 
there's no need to read the release to find out the results.

But then you would have missed this...

"The most frequently reported side effects were headaches..."

nig


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News